Basic research

Effects of Pcsk9 gene interference on high fat-induced nonalcoholic fatty liver disease with atherosclerosis in rats

  • Xiaowen ZHANG ,
  • Yi WANG ,
  • Chan ZHANG ,
  • Di ZHANG ,
  • Hang YUN ,
  • Di HUANG
Expand
  • 1.Department of Nursing, School of Health Management, Shangluo University, Shangluo 726000, China
    2.Shaanxi "Four Subjects and One Union" Qinling Health Food Ingredients and Walnut Industry Technology School-Enterprise Joint Research Center, Shangluo 726000, China
ZHANG Xiaowen, E-mail: zhangxiaowen0728@sina.com.

Received date: 2021-12-14

  Online published: 2022-03-17

Supported by

Shaanxi Provincial Department of Science and Technology 2021 Science and Technology Project(2021SF-326)

Abstract

Objective

·To investigate the effects of proprotein convertase subtilisin kexin 9 (Pcsk9) gene knockdown on non-alcoholic fatty liver disease (NAFLD) and atherosclerotic lesions in rats induced by high fat.

Methods

·The SD rat model of NAFLD was established. Rats were randomly divided into 4 groups: control group, model group (high fat), shRNA-negative control (NC) interference model group (high fat+shRNA-NC) and Pcsk9-shRNA interference model group (high fat+ Pcsk9-shRNA). Real-time quantitative polymerase chain reaction (RT-qPCR) was used to detect Pcsk9 gene interference efficiency. Fasting serum insulin was determined by radioimmunoassay. Automatic biochemical analyzer was used to detect levels of blood lipid in rats. Hematoxylin-eosin staining (H-E staining) was used to observe the injury of liver tissue and aorta tissue. Apoptosis of liver tissue was detected by TUNEL staining. The levels of interleukin-1β (IL-1β), IL-6 and inducible nitric oxide synthase (iNOS) in peripheral blood were detected by enzyme linked immunosorbent assay (ELISA). The expression of PCSK9, Toll-like receptor 4 (TLR4), nuclear factor κB (NF-κB) P65 and tumor necrosis factor α (TNF-α) were detected by Western blotting.

Results

·Compared with the control group, obesity index and insulin level in the model group were significantly increased (all P=0.000); the apoptosis rate of liver cells was significantly increased (P=0.000); the level of high density lipoprotein cholesterol (HDL-C) was significantly decreased, while the levels of low density lipoprotein cholesterol (LDL-C), total cholesterol (TC) and triacylglycerol (TAG) were significantly increased (all P=0.000); the levels of IL-1β, IL-6 and iNOS were significantly increased (all P=0.000); TLR4, NF-κB P65 protein activation and TNF-α expression were significantly increased (all P=0.000); the liver tissue and aorta tissue were significantly damaged. After interferenceof Pcsk9 gene expression, compared with the model group, obesity index and insulin level in the high fat+Pcsk9-shRNA group were significantly reduced (P=0.007, P=0.000); the apoptosis rate of liver cells was significantly reduced (P=0.000); the level of HDL-C was significantly increased while the levels of LDL-C, TC and TAG were significantly decreased (all P=0.000); the levels of IL-1β, IL-6 and iNOS were significantly decreased (all P=0.000); TLR4, NF-κB P65 protein activation and TNF-α expression were significantly decreased (all P=0.000); the histopathological lesions of liver tissue and aorta tissue were improved.

Conclusion

·Knockdown of Pcsk9 gene can reduce obesity index, insulin level, blood lipid index and inflammatory response in the rats with NAFLD and atherosclerosis, and inhibit the activation of TLR4 and NF-κB P65 protein, thereby improving the injury of liver and aortic tissue in rats.

Cite this article

Xiaowen ZHANG , Yi WANG , Chan ZHANG , Di ZHANG , Hang YUN , Di HUANG . Effects of Pcsk9 gene interference on high fat-induced nonalcoholic fatty liver disease with atherosclerosis in rats[J]. Journal of Shanghai Jiao Tong University (Medical Science), 2022 , 42(2) : 150 -157 . DOI: 10.3969/j.issn.1674-8115.2022.02.003

References

1 HAN Y M, LEE Y J, JANG Y N, et al. Aspirin improves nonalcoholic fatty liver disease and atherosclerosis through regulation of the PPARδ-AMPK-PGC-1α pathway in dyslipidemic conditions[J]. Biomed Res Int, 2020, 2020: 7806860.
2 GRATTAGLIANO I, DI CIAULA A, BAJ J, et al. Protocols for mitochondria as the target of pharmacological therapy in the context of nonalcoholic fatty liver disease (NAFLD)[J]. Methods Mol Biol, 2021, 2310: 201-246.
3 YOUNOSSI Z, ANSTEE Q M, MARIETTI M, et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention[J]. Nat Rev Gastroenterol Hepatol, 2018, 15(1): 11-20.
4 刘艳如, 温晓华, 高冕, 等. 非肥胖人群血浆致动脉硬化指数与非酒精性脂肪性肝病的相关性[J]. 临床误诊误治, 2021, 34(10): 94-98.
5 CAI J, ZHANG X J, JI Y X, et al. Nonalcoholic fatty liver disease pandemic fuels the upsurge in cardiovascular diseases[J]. Circ Res, 2020, 126(5): 679-704.
6 SCICALI R, DI PINO A, URBANO F, et al. Analysis of steatosis biomarkers and inflammatory profile after adding on PCSK9 inhibitor treatment in familial hypercholesterolemia subjects with nonalcoholic fatty liver disease: a single lipid center real-world experience[J]. Nutr Metab Cardiovasc Dis, 2021, 31(3): 869-879.
7 马春艳, 徐瑞霞, 姚雨宏, 等. 冠心病患者血浆PCSK9水平与低密度脂蛋白亚组分的相关性研究[J]. 中国分子心脏病学杂志, 2017, 17(4): 2167-2170.
8 THEOCHARIDOU E, PAPADEMETRIOU M, REKLOU A, et al. The role of PCSK9 in the pathogenesis of non-alcoholic fatty liver disease and the effect of PCSK9 inhibitors[J]. Curr Pharm Des, 2018, 24(31): 3654-3657.
9 耿妍, 鲁晓岚, 耿燕, 等. 肠道菌群紊乱在大鼠非酒精性脂肪肝中的作用机制[J]. 分子诊断与治疗杂志, 2020, 12(12): 1626-1630.
10 李滨, 张佳圆, 王凤永, 等. 胆宁片治疗非酒精性脂肪肝临床效果及对血脂、肝功能和肝纤维化的影响[J]. 解放军医药杂志, 2018, 30(10): 93-96.
11 DEMERS A, SAMAMI S, LAUZIER B, et al. Pcsk9 induces CD36 degradation and affects long-chain fatty acid uptake and triglyceride metabolism in adipocytes and in mouse liver [J]. Arterioscler Thromb Vasc Biol, 2015, 35(12): 2517-2525.
12 LEBEAU P F, BYUN J H, PLATKO K, et al. Pcsk9 knockout exacerbates diet-induced non-alcoholic steatohepatitis, fibrosis and liver injury in mice[J]. JHEP Rep, 2019, 1(6): 418-429.
13 王娟, 娜丽, 张迎军, 等. 血清TLR4、HMGB1、IL-6与非酒精性脂肪性肝病患者动脉粥样硬化的相关性[J]. 中西医结合肝病杂志, 2021, 31(8): 712-714.
14 LI M, XU C, SHI J, et al. Fatty acids promote fatty liver disease via the dysregulation of 3-mercaptopyruvate sulfurtransferase/hydrogen sulfide pathway[J]. Gut, 2018, 67(12): 2169-2180.
15 DEWIDAR B, KAHL S, PAFILI K, et al. Metabolic liver disease in diabetes-from mechanisms to clinical trials[J]. Metabolism, 2020, 111S: 154299.
16 PEDERSEN J S, RYGG M O, KRISTIANSEN V B, et al. Nonalcoholic fatty liver disease impairs the liver-alpha cell axis independent of hepatic inflammation and fibrosis[J]. Hepatol Commun, 2020, 4(11): 1610-1623.
17 MUHAMMAD T, IKRAM M, ULLAH R, et al. Hesperetin, a citrus flavonoid, attenuates LPS-induced neuroinflammation, apoptosis and memory impairments by modulating TLR4/NF-κB signaling[J]. Nutrients, 2019, 11(3): 648.
18 CHEN M, XING J, PAN D, et al. Chinese herbal medicine mixture 919 syrup alleviates nonalcoholic fatty liver disease in rats by inhibiting the NF-κB pathway[J]. Biomed Pharmacother, 2020, 128: 110286.
Outlines

/